These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Non-Alcoholic Fatty Liver Disease, an Overview. Nd AM Integr Med (Encinitas); 2019 Apr; 18(2):42-49. PubMed ID: 31341444 [TBL] [Abstract][Full Text] [Related]
26. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments. Roeb E; Geier A Z Gastroenterol; 2019 Apr; 57(4):508-517. PubMed ID: 30965381 [TBL] [Abstract][Full Text] [Related]
27. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Sugimoto K; Inui H; Fukusato T World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263 [TBL] [Abstract][Full Text] [Related]
28. Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention. Mao T; Sun Y; Xu X; He K Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37756016 [TBL] [Abstract][Full Text] [Related]
29. Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH. Hydes TJ; Ravi S; Loomba R; E Gray M Clin Mol Hepatol; 2020 Oct; 26(4):383-400. PubMed ID: 32674529 [TBL] [Abstract][Full Text] [Related]
30. [TEN-HOUR INTERMITTENT FASTING PLUS MEDITERRANEAN DIET VERSUS MEDITERRANEAN DIET ALONE FOR TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)]. Milgrom Y; Massarwa M; Hazou W; Shafrir A; Mishraki E; Sanduka S; Safadi R; Benson A Harefuah; 2024 Feb; 163(2):93-96. PubMed ID: 38431857 [TBL] [Abstract][Full Text] [Related]
31. Nutritional Approaches for the Management of Nonalcoholic Fatty Liver Disease: An Evidence-Based Review. Parra-Vargas M; Rodriguez-Echevarria R; Jimenez-Chillaron JC Nutrients; 2020 Dec; 12(12):. PubMed ID: 33348700 [TBL] [Abstract][Full Text] [Related]
32. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Soejima Y; Fukusato T World J Gastroenterol; 2012 May; 18(19):2300-8. PubMed ID: 22654421 [TBL] [Abstract][Full Text] [Related]
34. Favorable association between Mediterranean diet (MeD) and DASH with NAFLD among Iranian adults of the Amol Cohort Study (AmolCS). Doustmohammadian A; Clark CCT; Maadi M; Motamed N; Sobhrakhshankhah E; Ajdarkosh H; Mansourian MR; Esfandyari S; Hanjani NA; Nikkhoo M; Zamani F Sci Rep; 2022 Feb; 12(1):2131. PubMed ID: 35136128 [TBL] [Abstract][Full Text] [Related]
35. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis. Hohenester S; Christiansen S; Nagel J; Wimmer R; Artmann R; Denk G; Bischoff M; Bischoff G; Rust C Am J Physiol Gastrointest Liver Physiol; 2018 Sep; 315(3):G329-G338. PubMed ID: 29878845 [TBL] [Abstract][Full Text] [Related]
36. Nonalcoholic fatty liver disease: lifestyle and quality of life. Vachliotis I; Goulas A; Papaioannidou P; Polyzos SA Hormones (Athens); 2022 Mar; 21(1):41-49. PubMed ID: 34854066 [TBL] [Abstract][Full Text] [Related]
37. Baseline HOMA IR and Circulating FGF21 Levels Predict NAFLD Improvement in Patients Undergoing a Low Carbohydrate Dietary Intervention for Weight Loss: A Prospective Observational Pilot Study. Watanabe M; Risi R; Camajani E; Contini S; Persichetti A; Tuccinardi D; Ernesti I; Mariani S; Lubrano C; Genco A; Spera G; Gnessi L; Basciani S Nutrients; 2020 Jul; 12(7):. PubMed ID: 32708435 [TBL] [Abstract][Full Text] [Related]
38. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. Brown E; Hydes T; Hamid A; Cuthbertson DJ Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271 [TBL] [Abstract][Full Text] [Related]
39. Gut Permeability Might be Improved by Dietary Fiber in Individuals with Nonalcoholic Fatty Liver Disease (NAFLD) Undergoing Weight Reduction. Krawczyk M; Maciejewska D; Ryterska K; Czerwińka-Rogowska M; Jamioł-Milc D; Skonieczna-Żydecka K; Milkiewicz P; Raszeja-Wyszomirska J; Stachowska E Nutrients; 2018 Nov; 10(11):. PubMed ID: 30453660 [TBL] [Abstract][Full Text] [Related]
40. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]